Pembrolizumab plus reduced-dose ipilimumab confers durable antitumor activity in advanced melanoma

Source: Healio, June 2017

CHICAGO — The combination of standard-dose pembrolizumab and low-dose ipilimumab led to robust and durable antitumor activity with a manageable safety profile in patients with advanced melanoma, according to mature data from KEYNOTE-029.

“The main question we asked was, ‘Can we get the efficacy of standard-dose ipilimumab [Yervoy, Bristol-Myers Squibb] with low-dose PD-1, but with less toxicity, by changing the ratios?’” Matteo S. Carlino, MBBS, PhD, clinical senior lecturer in Westmead Clinical School of The University of Sydney and oncologist in the department of medical oncology at Westmead Hospital, told HemOnc Today.

Earlier results from the trial showed standard-dose pembrolizumab (Keytruda, Merck) with reduced-dose ipilimumab was safe and effective in patients with advanced melanoma.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories